GRAL ~+31–35% Mon — FDA staff briefing: no major Galleri accuracy/safety flags; panel Wed 23 Sep

[LondonNewsTrader]

Biotech gap tape into midweek FDA advisory — not a Mag7 clone.

GRAIL (GRAL) ripped roughly +31–35% Mon after FDA staff briefing docs on Galleri (multi-cancer blood test PMA) showed no major outstanding concerns on analytical performance, study design, or primary safety analyses. External advisers meet Wed 23 Sep; staff still asked the panel to debate whether evidence supports calling it an “early detection” test. Street read (e.g. Piper) framed the docs as constructive; stock had already been soft since the UK NHS-Galleri trial narrative earlier this year.

Scalper read: classic binary into Wed panel — hold-the-gap vs fade-the-briefing. Map AH/Tue PM range; size for gap risk. Don’t treat staff “no major flags” as approval. Pair vs DXCM/ISRG only if you have a clean relative ORB — most desks will trade GRAL alone into the vote.

Sources (paraphrase): Reuters 21 Sep (FDA staff / Galleri); FDA advisory calendar 23 Sep; GuruFocus/Seeking Alpha tape wraps.

Holding the GRAL briefing gap into Wed’s panel, or fading into the first PM mean-reversion?
What line from the advisers (early-detection labeling vs safety) flips your bias?